Sclerostin deficiency modifies the development of CKD-MBD in mice.
Sign Up to like & getrecommendations! Published in 2018 at "Bone"
DOI: 10.1016/j.bone.2017.11.015
Abstract: Sclerostin is a soluble antagonist of canonical Wnt signaling and a strong inhibitor of bone formation. We present experimental data on the role of sclerostin in chronic kidney disease - bone mineral disorder (CKD-MBD). METHODS… read more here.
Keywords: ckd mbd; bone; sclerostin deficiency; mice ... See more keywords